The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer

  • Marie Terroir
  • Isabelle Borget
  • François Bidault
  • Marcel Ricard
  • Frédéric Deschamps
  • Dana Hartl
  • Lambros Tselikas
  • Laurent Dercle
  • Jean Lumbroso
  • Eric Baudin
  • Amandine Berdelou
  • Désirée Deandreis
  • Martin Schlumberger
  • Sophie Leboulleux
Original Article

Abstract

Purpose

In patients with metastatic differentiated thyroid carcinoma (DTC), fluorodeoxyglucose (FDG) uptake as well as age, tumor size and radioactive iodine (RAI) uptake are prognostic factors for survival. High FDG uptake is a poor prognostic factor and lesions with high FDG uptake are often considered aggressive, but the predictive value of FDG uptake for morphological progression is unknown. The principal aim of this retrospective single center study was to determine whether the intensity of FDG uptake was correlated on a per lesion analysis with tumor growth rate (TGR) expressed as the percentage of increase in tumor size during 1 year (1-year TGR).

Methods

Fifty five patients with DTC were included between July 2012 and May 2014 with the following criteria: (i) at least one distant metastasis measuring ≥ 1 cm in diameter on CT scan (ii) evaluation by FDG-positron emission tomography/computed tomography (PET/CT) performed at our center (iii) at least one CT or another FDG-PET/CT performed 3 to 12 months after the reference FDG-PET/CT in the absence of systemic or local treatment between the two imaging procedures.

Results

One hundred and fifty-six metastatic lesions located in lungs (63), neck lymph nodes (28), chest lymph nodes (42), bone (11), liver (2) and other sites (12) were studied. The median size was 16 mm, median SUVmax/lesion: 8.7; median metabolic tumor volume/lesion (Metab.TV/lesion): 3.7 cm3. The median 1-year TGR was 40.68 %. SUVmax and Metab.TV/lesion were not correlated to their 1-year TGR (p = 0.38 and p = 0.74 respectively). Among single patients with multiple lesions, the lesions with the highest SUVmax/lesion or the highest Metab.TV/lesion did not disclose the higher 1-year TGR.

Conclusion

The intensity of FDG uptake on a per lesion analysis is not correlated to its 1-year TGR and cannot be used as a surrogate marker of tumour progression.

Keywords

18FDG PET/CT Differentiated thyroid cancer Metastases Tumor growth rate 

References

  1. 1.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid Off J Am Thyroid Assoc. 2016;26:1–133.CrossRefGoogle Scholar
  2. 2.
    Cazzato RL, Bonichon F, Buy X, Godbert Y, de Figuereido BH, Pointillart V, et al. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2015;41:1247–55.Google Scholar
  3. 3.
    de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26:987–91.CrossRefGoogle Scholar
  4. 4.
    Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18:159–69.CrossRefPubMedGoogle Scholar
  5. 5.
    Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498–505.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–13.PubMedGoogle Scholar
  7. 7.
    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl. 2009;45:228–47.CrossRefGoogle Scholar
  9. 9.
    Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer Oxf Engl. 2011;47:2512–6.CrossRefGoogle Scholar
  10. 10.
    Ferté C, Koscielny S, Albiges L, Rocher L, Soria J-C, Iacovelli R, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol. 2014;65:713–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, et al. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med Off Publ Soc Nucl Med. 2009;50:1760–9.Google Scholar
  12. 12.
    Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Sacks W, Braunstein GD. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20:263–75.Google Scholar
  14. 14.
    Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009;94:1310–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Tubiana MLH. Gray medal lecture: cell kinetics and radiation oncology. Int J Radiat Oncol Biol Phys. 1982;8:1471–89.CrossRefPubMedGoogle Scholar
  16. 16.
    Masson-Deshayes S, Schvartz C, Dalban C, Guendouzen S, Pochart J-M, Dalac A, et al. Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers. Clin Nucl Med. 2015;40:469–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, Foppiani L, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:874–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Kelders A, Kennes LN, Krohn T, Behrendt FF, Mottaghy FM, Verburg FA. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions. Nucl Med Commun. 2014;35:176–81.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Marie Terroir
    • 1
  • Isabelle Borget
    • 2
  • François Bidault
    • 3
  • Marcel Ricard
    • 4
  • Frédéric Deschamps
    • 5
  • Dana Hartl
    • 6
  • Lambros Tselikas
    • 5
  • Laurent Dercle
    • 1
  • Jean Lumbroso
    • 1
  • Eric Baudin
    • 1
  • Amandine Berdelou
    • 1
  • Désirée Deandreis
    • 1
  • Martin Schlumberger
    • 1
  • Sophie Leboulleux
    • 1
  1. 1.Department of Nuclear Medicine and Endocrine OncologyGustave Roussy and Université Paris SaclayVillejuifFrance
  2. 2.Department of Biostatistics and Epidemiology, Gustave RoussyUniversity Paris SudVillejuifFrance
  3. 3.Department of RadiologyGustave RoussyVillejuifFrance
  4. 4.Department of PhysicGustave RoussyVillejuifFrance
  5. 5.Department of Interventional RadiologyVillejuifFrance
  6. 6.Department of SurgeryGustave RoussyVillejuifFrance

Personalised recommendations